Cognitive Rehabilitation of Deficits in Patients With Multiple Scleros
Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis: Proposal for an Integrated Cognitive Treatment in a Telematic Format
What it found
No result yet.
What was tested
Treatment tested
- Cognitive treatment delivered via telerehabilitation.
Compared with
- In-person cognitive treatment.
What it measured
Main measures
Paced Auditory Serial Addition Task (PASAT)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Thinking and memory
Other measures (10)
Trail Making Test Part A (TMT-A)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Thinking and memoryTrail Making Test Part B (TMT-B)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Thinking and memorySymbol Digit Modalities Test
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Thinking and memoryModified Five Point Test (MFPT)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
"Learning" subtest of the Rivermead Behavioural Memory Test-3 (RBMT-3)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Thinking and memoryPhonemic Verbal Fluency Test
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Test of Attentional Performance (TAP)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Thinking and memoryModified Fatigue Impact Scale (MFIS)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
FatigueMultiple Sclerosis Quality of Life 54 (MSQOL-54)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Quality of life (reported by participants)Depression, Anxiety, and Stress Scale (DASS)
The test is administered before the treatment, then after eight weeks of treatment, and finally two months after the end of the treatmen
Mood and sleep
Who could take part
Relapsing and progressive · 18 to 65 · EDSS 3 to 5
Show the full criteria
Inclusion criteria
* Diagnosis of relapsing-remitting multiple sclerosis (RRMS), or primary progressive (PPMS) or secondary progressive (SPMS), defined by at least 3-6 months. * Age between 18 and 65 years. * Expanded Disability Status Scale (EDSS) between 3 and 5 to include patients with overall neurological disability from mild to moderate. * Presence of one or more of the following cognitive disorders (reported by the patient and subsequently confirmed through the Oxford Cognitive Screen-OCS): * Memory disorders * Attention disorders * Executive function disorders * Availability of internet at the patient's home necessary for the tele-rehabilitation procedures. * Adequate visual and auditory abilities to use the rehabilitation device.
Exclusion criteria
* Presence of other neurological conditions; * Psychiatric disorders in medical history; * Alcohol and/or drug abuse; * Presence of uncorrected severe visual deficits.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
Non-Inferiority Study, Post-Market Clinical Investigation with a Device, Single-Blind Randomized Controlled Trial in a Cohort of Patients Diagnosed with Multiple Sclerosis (MS). The aim of the study is to assess whether a computer-based cognitive treatment delivered via telerehabilitation produces effects from T0 to T1 that are not inferior to those of an in-person treatment on sustained attention in a cohort of patients with MS. The secondary objective is to evaluate the effects of telerehabilitation compared to the same treatment delivered in person on attentional shifting, memory, executive functions, and daily functioning (including cognitive fatigue, quality of life, and mood) in patients with MS.
Loading reviews and guidelines…
History
Started
Feb 2023
Main results due
Apr 2025
Finished
Sept 2025